Pharmacyclics (PCYC +3.8%) trades higher after the FDA designates Orphan Drug Status for its...

|By:, SA News Editor

Pharmacyclics (PCYC +3.8%) trades higher after the FDA designates Orphan Drug Status for its chronic lymphocyctic leukemia treatment.